Amylyx Pharmaceuticals Dividenden en inkoop
Dividend criteriumcontroles 0/6
Amylyx Pharmaceuticals heeft geen dividenduitkeringen gedaan.
Belangrijke informatie
n/a
Dividendrendement
-0.1%
Terugkoop Rendement
| Totaal aandeelhoudersrendement | -0.1% |
| Toekomstig dividendrendement | 0% |
| Dividendgroei | n/a |
| Volgende betaaldatum dividend | n/a |
| Ex-dividenddatum | n/a |
| Dividend per aandeel | n/a |
| Uitbetalingsratio | n/a |
Recente updates van dividend en inkoop
Geen updates
Recent updates
Narratiefupdate • Aug 20
AMLX: LUCIDITY Success Will Expose Overoptimistic Hopes For PBH Commercial Rollout
Amylyx Pharmaceuticals’ updated analyst price target framework now centers on an implied fair value of $22.63 per share, with analysts citing the strong Phase 3 LUCIDITY data for avexitide in post-bariatric hypoglycemia and the potential for a sizable treatment opportunity as key drivers of their revised assumptions. Analyst Commentary Street research on Amylyx Pharmaceuticals has turned more constructive following the Phase 3 LUCIDITY readout for avexitide in post bariatric hypoglycemia, with several firms revising their valuation models and price targets to reflect the trial outcomes and the size of the potential treatment pool.Seeking Alpha • Aug 18
Amylyx: Upgraded To Strong Buy On LUCIDITY Outcome, Avexitide, And 2026 Catalysts
Summary Amylyx Pharmaceuticals, Inc. is upgraded to Strong Buy after positive phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia [PBH]. Avexitide met its primary endpoint, achieving a 55% reduction in severe hypoglycemic events, with strong statistical significance and a favorable safety profile. Key catalysts include an NDA submission for avexitide in PBH by end-2026 and medical data presentation in 2026; expansion into long-acting GLP-1 antagonist AMX0318 is underway. Despite a projected cash runway into 2028, company may need to raise capital in 2027; Cash raise possible early as today because of stock trading significantly higher. Read the full article on Seeking Alpha
Narratiefupdate • Aug 06
AMLX: Q3 LUCIDITY Outcome Will Shape View On Undervalued Opportunity
Amylyx Pharmaceuticals' updated analyst price target of $25.56, up from $24.40, reflects analysts' focus on the upcoming Phase 3 LUCIDITY readout for avexitide in post bariatric hypoglycemia and the related sales potential cited in recent research. Analyst Commentary Recent research on Amylyx Pharmaceuticals centers on the Phase 3 LUCIDITY study of avexitide in post bariatric hypoglycemia, with several firms updating their price targets and framing both upside potential and execution risks around this single pivotal catalyst.Narratiefupdate • Jul 10
AMLX: Phase 3 LUCIDITY Readout Will Drive View On Undervalued Potential
The analyst fair value estimate for Amylyx Pharmaceuticals has been adjusted from $22.20 to $24.40 as analysts reference higher Street price targets, including Guggenheim's move to $40 and the stock's inclusion as a "Best Idea." This is supported by expectations around the upcoming Phase 3 LUCIDITY readout for avexitide in post-bariatric hypoglycemia and the potential of the $6b+ US PBH market. Analyst Commentary Recent Street research on Amylyx Pharmaceuticals focuses heavily on the upcoming Phase 3 LUCIDITY readout for avexitide in post-bariatric hypoglycemia, with valuation views closely tied to how analysts frame the opportunity in the US PBH market and the stock's execution risks around this catalyst.
Narratiefupdate • Jun 26
AMLX: Upcoming PBH Phase 3 Readout Will Drive Bullish Repricing
Amylyx Pharmaceuticals' updated analyst price target has shifted from about $32.63 to roughly $37.58, with analysts citing the stock's inclusion on select "Best Idea" lists and expectations around upcoming LUCIDITY trial results as key reasons for the change. Analyst Commentary Recent Street research on Amylyx Pharmaceuticals highlights a cluster of upbeat views ahead of the LUCIDITY Phase 3 readout for avexitide in post-bariatric hypoglycemia.Nieuw narratief • Apr 02
Bullish View That Future PBH Therapy Breakthrough Will Underpin Long Term Upside Potential
Catalysts About Amylyx Pharmaceuticals Amylyx Pharmaceuticals focuses on developing therapies for endocrine and neurodegenerative conditions, with a current emphasis on post bariatric hypoglycemia and ALS. What are the underlying business or industry changes driving this perspective?Nieuw narratief • Mar 19
Post Bariatric Hypoglycemia Setbacks Will Pressure Earnings Before Long Term Endocrine Potential Emerges
Catalysts About Amylyx Pharmaceuticals Amylyx Pharmaceuticals is a biopharmaceutical company focused on treatments for endocrine conditions such as post bariatric hypoglycemia and neurodegenerative diseases including ALS and Wolfram syndrome. What are the underlying business or industry changes driving this perspective?Nieuw narratief • Mar 05
PBH Franchise And Neurodegeneration Pipeline Will Support A Stronger Future Business Model
Catalysts About Amylyx Pharmaceuticals Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing treatments for endocrine disorders and neurodegenerative diseases. What are the underlying business or industry changes driving this perspective?Analyse-artikel • Sep 01
Here's Why We're A Bit Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Amylyx Pharmaceuticals...Analyse-artikel • May 10
Can Amylyx Pharmaceuticals (NASDAQ:AMLX) Afford To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyse-artikel • Apr 03
Optimistic Investors Push Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Up 26% But Growth Is Lacking
Those holding Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares would be relieved that the share price has rebounded...Seeking Alpha • Feb 24
Amylyx Pharmaceuticals: Lots Of Setbacks, Some Chances Of Recovery
Summary AMLX has had major setbacks in its lifecycle, including the voluntary withdrawal of an approved drug. The company purchased late-stage assets from a bankrupt company and are running them through trials. Considerable risks remain as to the market, and whether AMLX can overcome its streak of bad luck. Read the full article on Seeking AlphaAnalyse-artikel • Dec 19
Little Excitement Around Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Revenues As Shares Take 26% Pounding
The Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) share price has softened a substantial 26% over the previous 30 days...Analyse-artikel • Dec 10
Is Amylyx Pharmaceuticals (NASDAQ:AMLX) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Seeking Alpha • Nov 25
Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along
Summary The company reported positive results from the phase 2 HELIOS study of AMX0035 for Wolfram Syndrome, setting up initiation of a potential phase 3 trial in 2025. An interim analysis of the phase 2b/3 ORION trial for Progressive Supranuclear Palsy is expected in mid-2025, determining the program's future. Financially, Amylyx has $234.4 million in cash, enough to fund operations into 2026, but may need to raise additional funds in 2025. Avexitide, an acquired GLP-1 receptor antagonist for patients with post-bariatric hypoglycemia, is expected to start a phase 3 study in Q1 of 2025, with data expected in 2026. Read the full article on Seeking AlphaAnalyse-artikel • Nov 04
There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise
Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares have continued their recent momentum with a 81% gain in the last...Analyse-artikel • Sep 18
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry
Amylyx Pharmaceuticals, Inc. ( NASDAQ:AMLX ) shares have continued their recent momentum with a 37% gain in the last...Seeking Alpha • Jun 25
Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
Summary Amylyx Pharmaceuticals, Inc.'s relyvrio for ALS was voluntarily delisted in the U.S. and Canada, but has a chance to target this indication with the advancement of AMX0114; IND filing and trial initiation expected in 2024. Full data from the phase 2 HELIOS trial, using AMX0035 to treat patients with Wolfram syndrome, is expected Fall of 2024. Interim analysis from phase 3 ORION study, using AMX0035 to treat patients with progressive supranuclear palsy, expected mid-2025. The company could possibly acquire rights to phase 3 ready GLP-1 asset Avexitide; This depends upon meeting certain conditions under this agreement, including a favorable ruling from the Texas Bankruptcy Court. Read the full article on Seeking AlphaStabiliteit en groei van betalingen
Dividenden ophalen
Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van AMLX in het verleden stabiel is geweest.
Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van AMLX zijn gestegen.
Dividendrendement versus markt
| Amylyx Pharmaceuticals Dividendrendement versus markt |
|---|
| Segment | Dividendrendement |
|---|---|
| Bedrijf (AMLX) | n/a |
| Markt onderkant 25% (US) | 1.3% |
| Markt Top 25% (US) | 4.0% |
| Gemiddelde industrie (Pharmaceuticals) | 1.8% |
| Analist prognose (AMLX) (tot 3 jaar) | 0% |
Opmerkelijk dividend: Het dividendrendement van AMLX kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.
Hoog dividend: Het dividendrendement van AMLX kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.
Winstuitkering aan aandeelhouders
Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio AMLX te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.
Contante uitbetaling aan aandeelhouders
Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat AMLX geen uitbetalingen heeft gerapporteerd.
Ontdek bedrijven met een sterk dividend
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/20 05:16 |
| Aandelenkoers aan het einde van de dag | 2026/08/20 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Amylyx Pharmaceuticals, Inc. wordt gevolgd door 14 analisten. 11 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| null null | Baird |
| Christopher Chen | Baird |
| Joel Beatty | Baird |